A Systematic Review on Interferon Alpha-Induced Cognitive Impairment in Hepatitis C Patients

Curr Drug Saf. 2023;18(2):159-166. doi: 10.2174/1574886317666220428134931.

Abstract

Objective: Interferon-alpha (IFN-α) is an important treatment modality for the hepatitis C virus (HCV). However, treatment with IFN-α is often associated with cognitive difficulties in HCV patients. Thus, this systematic review was performed to assess the effects of IFN-α on cognitive functioning in patients suffering from HCV.

Methods: Relevant literature was identified by performing a comprehensive literature search in major databases including PubMed, clinicaltrials.gov, and Cochrane Central using a combination of suitable keywords. We retrieved studies that were published from the start of each database until August 2021.

Results: Out of 210 articles, 73 studies were selected after removing the duplicates. In the first pass, 60 articles were excluded. Out of 13 full-text articles, only 5 articles qualified for qualitative analyses in the second pass. We observed conflicting results concerned with the use of IFN-α and the risk of neurocognitive impairment in HCV patients.

Conclusion: In conclusion, we have observed conflicting results regarding the impact of INF-α treatment on the cognitive functioning of patients suffering from HCV. Thus, there is an urgent need for an extensive study to evaluate the exact association between INF-αtherapy and cognitive functioning in HCV patients.

Keywords: Hepatitis C virus; IFN-α; cognitive impairment; hepatitis C patients; interferon-alpha; neurocognition.

Publication types

  • Systematic Review

MeSH terms

  • Cognitive Dysfunction* / chemically induced
  • Cognitive Dysfunction* / diagnosis
  • Databases, Factual
  • Hepacivirus
  • Hepatitis C* / complications
  • Hepatitis C* / drug therapy
  • Humans
  • Interferon-alpha / adverse effects

Substances

  • Interferon-alpha